We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Novartis, BP and Biogen
Read MoreHide Full Article
For Immediate Release
Chicago, IL – February 9, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Novartis (NVS - Free Report) , BP (BP - Free Report) and Biogen (BIIB - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Research Reports for Novartis, BP and Biogen
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Novartis, BP and Biogen. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Novartis’ shares have underperformed the Zacks Large-Cap Pharmaceuticals industry (+0.8% vs. +3.2%), over the last six months. Novartis’ fourth-quarter results beat both earnings and sales estimates on strong performance of Cosentyx and Entresto. The generic division, Sandoz also combatted pricing pressure strongly buoyed by biosimilar launches of Rixathin and Erelzi.
Novartis has a strong oncology portfolio of drugs like Afinitor, Exjade, Jakavi, Zykadia, Tasigna, Jadenu and Kisqali. The approval of Kymriah for acute lymphoblastic leukemia is a major boost given the potential in the CAR-T therapy space.
Meanwhile, the strategic decision on Alcon to retain the business or separation via capital market transactions such as a spin-off or an initial public offering has been postponed for 2019. However, the loss of patent protection for some of the key drugs in Novartis’ portfolio is a cause of concern. Moreover, Kisqali’s uptake has been slow.
Shares of BP are up +16.1% over the last one year, outperforming the Zacks International Integrated Oil industry (up +7.2%). During 2017, the leading integrated energy firm brought online seven key upstream projects. BP is also expected to bring online five more developments in 2018.
All these projects along with the developments placed online during 2016 will likely help the energy giant add 800,000 barrels of oil equivalent per day to net production capacity by 2020. The firms’ fourth-quarter 2017 earnings skyrocketed year over year, courtesy of record oil and gas production and higher commodity price realizations.
However, the bottom line missed expectations, thanks to a surge in exploration expenses. Moreover, the oil spill incident of 2010 in the BP-operated Macondo Prospect continues to affect the company. BP anticipates cash out flow related to the incident of $3 billion through 2018 against the prior projection of slightly more than $2 billion.
Biogen’s shares have outperformed the Zacks Biomedical and Genetics industry over the last year (+20.9% vs. +0.8%). Biogen had a mixed fourth quarter as it beat estimates for earnings but missed the same for sales. However, Biogen issued an upbeat outlook for 2018.
Biogen has a strong position in the MS market with a wide range of products including Avonex, Tysabri, Tecfidera & Plegridy. The Zacks analyst likes its efforts to diversify beyond MS to other areas like Alzheimer’s, Parkinson's and stroke, among others. Meanwhile, its newest drug Spinraza has witnessed strong patient uptake in the U.S. and internationally.
However, weakening MS trends is a concern. Tecfidera is witnessing slight decline in U.S. patient demand due to increasing competition from oral medicines and a slowdown in the overall MS market. Meanwhile, the launch of Ocrevus by Roche is beginning to have a negative impact on MS franchise sales in the U.S., mainly on Tysabri.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performancefor information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Novartis, BP and Biogen
For Immediate Release
Chicago, IL – February 9, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Novartis (NVS - Free Report) , BP (BP - Free Report) and Biogen (BIIB - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Research Reports for Novartis, BP and Biogen
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Novartis, BP and Biogen. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Novartis’ shares have underperformed the Zacks Large-Cap Pharmaceuticals industry (+0.8% vs. +3.2%), over the last six months. Novartis’ fourth-quarter results beat both earnings and sales estimates on strong performance of Cosentyx and Entresto. The generic division, Sandoz also combatted pricing pressure strongly buoyed by biosimilar launches of Rixathin and Erelzi.
Novartis has a strong oncology portfolio of drugs like Afinitor, Exjade, Jakavi, Zykadia, Tasigna, Jadenu and Kisqali. The approval of Kymriah for acute lymphoblastic leukemia is a major boost given the potential in the CAR-T therapy space.
Meanwhile, the strategic decision on Alcon to retain the business or separation via capital market transactions such as a spin-off or an initial public offering has been postponed for 2019. However, the loss of patent protection for some of the key drugs in Novartis’ portfolio is a cause of concern. Moreover, Kisqali’s uptake has been slow.
Shares of BP are up +16.1% over the last one year, outperforming the Zacks International Integrated Oil industry (up +7.2%). During 2017, the leading integrated energy firm brought online seven key upstream projects. BP is also expected to bring online five more developments in 2018.
All these projects along with the developments placed online during 2016 will likely help the energy giant add 800,000 barrels of oil equivalent per day to net production capacity by 2020. The firms’ fourth-quarter 2017 earnings skyrocketed year over year, courtesy of record oil and gas production and higher commodity price realizations.
However, the bottom line missed expectations, thanks to a surge in exploration expenses. Moreover, the oil spill incident of 2010 in the BP-operated Macondo Prospect continues to affect the company. BP anticipates cash out flow related to the incident of $3 billion through 2018 against the prior projection of slightly more than $2 billion.
Biogen’s shares have outperformed the Zacks Biomedical and Genetics industry over the last year (+20.9% vs. +0.8%). Biogen had a mixed fourth quarter as it beat estimates for earnings but missed the same for sales. However, Biogen issued an upbeat outlook for 2018.
Biogen has a strong position in the MS market with a wide range of products including Avonex, Tysabri, Tecfidera & Plegridy. The Zacks analyst likes its efforts to diversify beyond MS to other areas like Alzheimer’s, Parkinson's and stroke, among others. Meanwhile, its newest drug Spinraza has witnessed strong patient uptake in the U.S. and internationally.
However, weakening MS trends is a concern. Tecfidera is witnessing slight decline in U.S. patient demand due to increasing competition from oral medicines and a slowdown in the overall MS market. Meanwhile, the launch of Ocrevus by Roche is beginning to have a negative impact on MS franchise sales in the U.S., mainly on Tysabri.
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performancefor information about the performance numbers displayed in this press release.